These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18260867)

  • 41. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
    Gurbel PA; Bliden KP; Tantry US
    J Am Coll Cardiol; 2006 Dec; 48(11):2186-91. PubMed ID: 17161243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
    King S; Short M; Harmon C
    Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome.
    Yakushkin VV; Zyuryaev IT; Khaspekova SG; Sirotkina OV; Ruda MY; Mazurov AV
    Platelets; 2011; 22(4):243-51. PubMed ID: 21329420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN; Wong SC; Bergman G; Minutello RM
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.
    Langford EJ; Wainwright RJ; Martin JF
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):51-5. PubMed ID: 8548426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Activity of blood platelets and functional state of endothelium in patients with unstable angina with favorable and unfavorable outcome (prospective study)].
    Voskoboi IV; Semenov AV; Mazurov AV; Kirichuk VF; Rebrov AP
    Kardiologiia; 2002; 42(9):4-11. PubMed ID: 12494065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy.
    Sambola A; García Del Blanco B; Ruiz-Meana M; Francisco J; Barrabés JA; Figueras J; Bañeras J; Otaegui I; Rojas A; Vilardosa Ú; Montaner J; García-Dorado D
    Thromb Haemost; 2016 Jun; 115(6):1129-37. PubMed ID: 26962963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor].
    Vaulin NA; Pokrovskaia EV; Deev AD; Gratsianskiĭ NA
    Kardiologiia; 2006; 46(6):37-42. PubMed ID: 16883221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension.
    Lip GY; Edmunds E; Hee FL; Blann AD; Beevers DG
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):823-8. PubMed ID: 11497201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlations of inhaled NO with the cTnI levels and the plasma clotting factor in rabbits with acute massive pulmonary embolism.
    Zhang Z; Meng Z; Wang Y
    Acta Cir Bras; 2018 Aug; 33(8):664-672. PubMed ID: 30208128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease.
    George R; Bhatt A; Narayani J; Thulaseedharan JV; Sivadasanpillai H; Tharakan JA
    Mol Cell Biochem; 2016 Aug; 419(1-2):125-33. PubMed ID: 27406211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Von Willebrand factor and soluble E-selectin in hyperlipidaemia: relationship to lipids and vascular disease.
    Blann AD; Davis A; Miller JP; McCollum CN
    Am J Hematol; 1997 May; 55(1):15-23. PubMed ID: 9136912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus.
    Yngen M; Ostenson CG; Li N; Hjemdahl P; Wallén NH
    Blood Coagul Fibrinolysis; 2001 Mar; 12(2):109-16. PubMed ID: 11302472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of aortic valve replacement on plasma soluble P-selectin, von Willebrand factor, and fibrinogen.
    Goldsmith IR; Blann AD; Patel RL; Lip GY
    Am J Cardiol; 2001 Jan; 87(1):107-10, A9. PubMed ID: 11137845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Soluble P-selectin in hyperlipidaemia with and without symptomatic vascular disease: relationship with von Willebrand factor.
    Blann AD; Goode GK; Miller JP; McCollum CN
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):200-4. PubMed ID: 9167022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atherosclerosis, myocardial infarction and primary hemostasis: Impact of platelets, von Willebrand factor and soluble glycoprotein VI.
    Villmann JM; Burkhardt R; Teren A; Villmann T; Thiery J; Drogies T
    Thromb Res; 2019 Aug; 180():98-104. PubMed ID: 31276978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.